<DOC>
	<DOCNO>NCT01778023</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial evaluate efficacy safety recombinant human growth hormone ( hGH ) subject idiopathic short stature Korea .</brief_summary>
	<brief_title>Efficacy Safety Recombinant Human Growth Hormone Height Velocity Subjects With Idiopathic Short Stature</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Informed consent obtain subject 's parent legally acceptable representative trialrelated activity . ( Trialrelated activity procedure would perform normal management subject . ) Prepubertal status ( male age 4 11 [ inclusive ] , female age 4 9 [ inclusive ] ) : absence breast development female ( Tanner 1 ) testicular volume 4 mL male Growth hormone level 10 ng/mL follow stimulation test ( test result within 6 month screen use ) Height 3 percentile Bone age equal 12 year Epiphyses confirm open patient least 10 year age Known presence one pituitary hormone deficiency ( ACTH ( adrenocorticotropic hormone ) , ADH ( antidiuretic hormone ) , FSH ( folliclestimulating hormone ) , LH ( luteinising hormone ) , TSH ( thyroidstimulating hormone ) ) Known primary hypothyroidism , adrenal insufficiency hypogonadism ( treat untreated ) Specific type growth failure include , limited , know chromosomal abnormality associate growth failure alter sensitivity growth hormone Bone age advance chronological age 3 year Active malignancy , CNS ( central nervous system ) trauma , active chemotherapy radiation therapy neoplasia Prior history intracranial hypertension Hypertrophic cardiomyopathy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>